Highlights
1. A randomized clinical trial within the Veterans Health Administration (VA) explored the impact of returning familial hypercholesterolemia (FH) genetic results to patients.
2. Although the primary outcome of LDL-C reduction did not reach statistical significance (P = .07), a trend toward benefit was observed with a reduction of -10.5 mg/dL in the immediate results arm.
3. Treatment intensification was more frequent in the immediate results group (20.0%) compared to the delayed group (8.8%).
4. Over 60% of participants who received immediate results shared them with relatives, highlighting the potential for cascade screening.
Introduction: The Burden of Unrecognized Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is a common but significantly underdiagnosed genetic disorder characterized by lifelong elevation of low-density lipoprotein cholesterol (LDL-C). With a prevalence of approximately 1 in 250 individuals, FH significantly increases the risk of premature atherosclerotic cardiovascular disease (ASCVD). Despite the availability of effective lipid-lowering therapies, many individuals with FH remain unidentified until after a major cardiovascular event occurs.
The advent of large-scale biobanks and research cohorts, such as the Million Veteran Program (MVP), has created a unique opportunity for “opportunistic” genomic screening. This involves identifying pathogenic variants for actionable conditions in individuals who underwent genetic testing for other reasons. However, a critical question remains for health systems and policymakers: does providing this genetic information to patients and clinicians actually lead to improved clinical outcomes, such as lower LDL-C levels?
Study Design: Integrating Research Data into Clinical Care
This randomized clinical trial (RCT) was conducted within the Veterans Health Administration and utilized the Million Veteran Program research biobank. The study targeted MVP enrollees who were suspected to carry a pathogenic or likely pathogenic variant associated with FH (specifically in the LDLR, APOB, or PCSK9 genes).
Participants were randomized into two groups:
1. Immediate Results Arm: Received clinical genetic confirmation testing and telegenetic counseling at the start of the study.
2. Delayed Results Arm: Received the same interventions after a 6-month wait, serving as the control group for the primary analysis.
The primary endpoint was the change in LDL-C levels from baseline to 6 months. Secondary endpoints included the proportion of patients achieving LDL-C targets, the rate of lipid-lowering therapy intensification, and the frequency of sharing results with family members. The trial enrolled 112 participants across 28 states, with a mean age of 65.9 years. Notably, 76.8% of these participants were already on some form of lipid-lowering therapy at baseline.
Key Findings: Impact on LDL-C and Clinical Management
At the 6-month mark, the results indicated a complex picture of the utility of genomic screening in an older, pre-treated population.
Primary Outcome: LDL-C Reduction
The mean baseline LDL-C level was 109.5 mg/dL. The immediate results arm showed a greater reduction in LDL-C compared to the delayed arm, with a between-group difference of -10.5 mg/dL (95% CI, -21.9 to 1.0; P = .07). While this did not meet the traditional threshold for statistical significance, the Cohen d effect size of 0.34 suggests a small to moderate effect. Exploratory Bayesian analysis indicated a high probability that the intervention provided at least some benefit.
Secondary Outcomes: Treatment and Targets
Treatment intensification—defined as starting a new medication or increasing the dose of an existing one—occurred in 20.0% of the immediate results arm compared to only 8.8% in the delayed arm (P = .09). Regarding target achievement, 27.3% of the immediate group reached their LDL-C goals compared to 24.6% in the control group (P = .74). These data suggest that while the genetic information may prompt clinicians to adjust therapy, reaching stringent LDL-C targets remains a challenge in clinical practice.
Cascade Screening Potential
One of the most promising findings was the impact on family communication. Among participants in the immediate results arm, 61.2% shared their genetic findings with a total of 98 relatives. This underscores the power of genomic screening not just for the individual, but as a catalyst for cascade testing in at-risk family members, which is a cornerstone of FH management.
Expert Commentary: Interpreting the Results in Clinical Context
The results of this trial offer a nuanced view of genomic medicine. The lack of statistical significance on the primary endpoint may be attributed to several factors. First, the sample size (n=112) was relatively small, which may have limited the power to detect a 10 mg/dL difference. Second, the study population was older (mean age ~66) and largely already treated. In a younger, treatment-naive population, the impact of a genetic diagnosis might be much more pronounced.
Clinicians should note that even in this older cohort, the disclosure of a genetic variant led to a nearly 10 mg/dL further reduction in LDL-C beyond standard care. In the context of cardiovascular risk, every 1 mmol/L (approx. 38.7 mg/dL) reduction in LDL-C is associated with a roughly 20-22% reduction in major vascular events. Therefore, a 10.5 mg/dL shift, if sustained across a population, could have meaningful public health implications.
The use of telegenetic counseling is also a significant takeaway. This model demonstrates that specialized genomic care can be delivered at scale across a national health system, overcoming geographical barriers to access for genetic specialists.
Strengths and Limitations
A major strength of this study is its randomized design within a real-world, national healthcare infrastructure. It bridges the gap between research-grade genomic data and clinical action. However, limitations include the predominantly male veteran population, which may limit generalizability to women and younger populations. Additionally, the 6-month follow-up period is relatively short for assessing long-term adherence to intensified lipid therapy or hard cardiovascular outcomes.
Conclusion: A Stepping Stone for Precision Cardiology
While the trial did not definitively prove that opportunistic FH screening significantly lowers LDL-C in all veterans, it provided strong signals of clinical utility. The trends toward improved lipid control and increased treatment intensification, combined with the high rate of family sharing, support the continued integration of genomic data into clinical workflows.
Future research should focus on optimizing the delivery of these results to primary care providers and patients, perhaps through automated electronic health record alerts, and investigating the cost-effectiveness of such programs on a larger scale. For now, the study reinforces the idea that a genetic diagnosis of FH can serve as a powerful motivator for both patients and providers to optimize cardiovascular preventive care.
Funding and Registration
This research was supported by the Department of Veterans Affairs, Veterans Health Administration, and the Million Veteran Program.
ClinicalTrials.gov Identifier: NCT04178122.
References
1. Vassy JL, Brunette CA, Yi T, et al. Opportunistic Genomic Screening for Familial Hypercholesterolemia to Improve Low-Density Lipoprotein Cholesterol: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(1):e2549664. doi:10.1001/jamanetworkopen.2025.49664.
2. Gidding SS, Champagne MA, de Ferranti SD, et al. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. 2015;132(22):2167-2192.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.